-transparent.png){kind=logo}
Vapreotide (RC-160), a somatostatin analog, was labeled with 99mTC by a direct method and also by using CPTA [1,4,8,11-tetraazacyclotetradecane] as a bifunctional chelating agent. The labeled compounds were evaluated in nude mice bearing experimental human prostate cancers. In these studies, 111In-DTPA-D-Phe-Octreotide (111In-DTPA-octreotide) served as a standard and 99mTc-oxytocin as a receptor-non-specific control. 99mTc-octreotide was also used. The 24 htumor uptake of 99mTc-RC-160 was nearly 400% higher, (p < 0.05), than that of 111In-DTPA-octreotide and diminished upon receptor blocking. In all tissues except the kidneys, the uptake of 99mTc-RC-160 was also higher than that of 111In-DTPA-octreotide. The uptake of 99mTc-RC-160 was influenced by the amount of peptide injected and the best tumor/muscle and tumor/blood ratios were obtained when only one micrograms of the peptide (200 Ci/mmol) was administered.
M L Thakur, and
H Kolan, and
J Li, and
R Wiaderkiewicz, and
V R Pallela, and
R Duggaraju, and
A V Schally
March 2011,
Endocrinology and metabolism clinics of North America,
M L Thakur, and
H Kolan, and
J Li, and
R Wiaderkiewicz, and
V R Pallela, and
R Duggaraju, and
A V Schally
September 2020,
Molecules (Basel, Switzerland),
M L Thakur, and
H Kolan, and
J Li, and
R Wiaderkiewicz, and
V R Pallela, and
R Duggaraju, and
A V Schally
February 2016,
Clinical nuclear medicine,
M L Thakur, and
H Kolan, and
J Li, and
R Wiaderkiewicz, and
V R Pallela, and
R Duggaraju, and
A V Schally
October 2016,
Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
M L Thakur, and
H Kolan, and
J Li, and
R Wiaderkiewicz, and
V R Pallela, and
R Duggaraju, and
A V Schally
May 2008,
Nuclear medicine and biology,
M L Thakur, and
H Kolan, and
J Li, and
R Wiaderkiewicz, and
V R Pallela, and
R Duggaraju, and
A V Schally
August 1996,
Nuclear medicine and biology,
M L Thakur, and
H Kolan, and
J Li, and
R Wiaderkiewicz, and
V R Pallela, and
R Duggaraju, and
A V Schally
May 2013,
Acta oncologica (Stockholm, Sweden),
M L Thakur, and
H Kolan, and
J Li, and
R Wiaderkiewicz, and
V R Pallela, and
R Duggaraju, and
A V Schally
February 2022,
Cancers,
M L Thakur, and
H Kolan, and
J Li, and
R Wiaderkiewicz, and
V R Pallela, and
R Duggaraju, and
A V Schally
March 2012,
Anticancer research,
M L Thakur, and
H Kolan, and
J Li, and
R Wiaderkiewicz, and
V R Pallela, and
R Duggaraju, and
A V Schally
April 2004,
Cancer biotherapy & radiopharmaceuticals,
